Torrent Pharma share price today

Torrent Pharmaceuticals Ltd's share price was ₹4,738.50 at the close on 4 November 2026. It has been rising for 183 weeks. That is 5.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹3,580 and ₹5,103, and at that close it sat 76% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Torrent Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

Over the last 11 years the share price moved +649% while the NIFTY 500 moved +257%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 13 quarters in a row (every quarter we can compare), indian funds and insurers (DIIs) raised their stake for 3 quarters in a row and number of shareholders up 82% in a year.

1. Revenue up on a year earlier for 13 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹4,979 crore, +50.8% on a year earlier.

   Why: Revenue rose because the company's India branded sales grew faster than the market, helped by Curatio and semaglutide.

   Next results: check whether semaglutide wins back share after supply came back.

   From the earnings call on 23 Oct 2026.

2. Indian funds and insurers (DIIs) raised their stake for 3 quarters in a row

   From 9% to 13.4% of the company by the September 2026 quarter.

3. Number of shareholders up 82% in a year

   1,42,140 shareholders in the September 2026 quarter, against 78,226 a year earlier.

For July to September 2026 (the quarter ended 30 September 2026), Torrent Pharma reported revenue of ₹4,979 crore, up 50.8% from ₹3,302 crore a year earlier, and a profit of ₹534 crore, down 9.6% from ₹591 crore.

Torrent Pharma results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Torrent Pharma's management discussed these results on a call held on 23 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Torrent Pharma closed at ₹4,738.50 on 4 November 2026, up 32.4% from ₹3,579.50 a year earlier (7 November 2025) and up 236.4% over five years. Its highest weekly close since February 2016 was ₹5,102.80 on 31 July 2026.

Torrent Pharma share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

565 weekly closes from 26 February 2016 to 4 November 2026.

4 Nov 2026: Torrent Pharma closed at ₹4,738.50, up 2.2% on the week and down 0.5% on the month. 23 Oct 2026: Torrent Pharma held its results call for July to September 2026. Management guided: Cost synergies around ₹450 crore, with roughly half in FY27 and most achieved within 2 years.

Earlier

• Results for July to September 2026: Revenue up 50.8% and profit down 9.6% on a year earlier.
• 29 May 2026: ex-date for a dividend of ₹9 a share.
• 18 Feb 2026: ex-date for an interim dividend of ₹29 a share, record date 19 Feb 2026.

Torrent Pharma paid ₹38 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 0.80% at the ₹4,738.50 close on 4 November 2026. The last was a dividend of ₹9 a share, ex-date 29 May 2026.

Torrent Pharma dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Torrent Pharmaceuticals Ltd paid out 59% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 23 October 2026, Torrent Pharma's management guided: Cost synergies around ₹450 crore, with roughly half in FY27 and most achieved within 2 years.

“Instead of 3 years, I think we should be able to get there in 2 years' time.”Sudhir Menon, on the call for July to September 2026

What management guided

• H2FY27 total JB growth to return to double digits, with India above double digits.
• H2 consolidated operating margin to edge above Q2; JB margins to improve gradually over the next 2-3 quarters.
• R&D spend at 4.2% of revenue in Q2 versus 3.5% in Q1, expected at 4%-4.5% next year; US filings and launches to support positive growth despite H2 price pressure.
• Brazil growth of 12%-15% in coming years; semaglutide launch expected in 6-9 months.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 23 October 2026.

When Torrent Pharma reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: JB international deliveries: check for normalization after plant-network, software, and quality-system changes.

Torrent Pharma is on one of our India lists: Pharma stocks.

Torrent Pharmaceuticals Ltd earned ₹534 Cr of net profit in the Sep 2026 quarter, −9.6% on the same quarter a year earlier. Full-year FY26 profit was ₹2,138 Cr. Over 10 years profit has grown 2.1% a year on average. That is 10.7% of the quarter's revenue. The same quarter a year earlier earned ₹591 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹2,138 Cr (+11.9% on the year before).

Why profit moved: revenue changed +50.8% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed −1.7% and revenue +41.3%. Profit is growing slower than sales: rising costs are taking part of the growth.

Torrent Pharmaceuticals Ltd reported ₹4,979 Cr of revenue in the Sep 2026 quarter, +50.8% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 7.7% a year on average. The last full year, FY26, came in at ₹13,980 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹17,400 Cr.

FY26 revenue was ₹13,980 Cr, +21.4% on the year before.

Recent pace: the last four quarters grew +41.3% on average, against 7.7% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +42.1%, against +24.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −1.9%, against +7.9% a year (rolling over).

Torrent Pharmaceuticals Ltd's operating margin was 33.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Across 13 years it has been between 22.0% and 41.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.7 percentage points on the year while gross margin changed −0.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 156% of Torrent Pharmaceuticals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹3,023 Cr of operating cash against ₹2,138 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹26,526 Cr of spending on assets, free cash was −₹23,503 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 156% of profit came in as cash: the cash cycle got 11 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 10.2× depreciation over three years. The next section checks what that spending is building.

Torrent Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 163 days in FY26, down from 174 days in FY21. It spent ₹27,668 Cr on assets over the last 3 years. Customers take 79 days to pay, and stock sits for 338 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹13,980 Cr, each day of that cycle ties up about ₹38.3 Cr, so roughly ₹6,243 Cr is tied up in the business at any time.

FY26: customers took 79 days to pay and stock sat for 338 days, about 11.1 months of sales sitting as stock, for a full cycle of 163 days, shorter than FY21's 174.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 338 days. Customers pay about 79 days after that. Suppliers are paid at 254 days. Together that makes the 163-day cycle.

Spending on assets: ₹27,668 Cr over the last 3 years, against ₹2,722 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹641 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Torrent Pharmaceuticals Ltd's P/E is 83.0×, about the highest it has ever been. Its usual P/E (the middle reading) is 41.7×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹60.28.